44,200.00
+300(+0.68%)
Currency In KRW
Address
A Building, Korea Bio Park
Seongnam-si, 13488
Korea, Republic of
Phone
82 3 1628 7666
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
50
First IPO Date
January 17, 2007
| Name | Title | Pay | Year Born |
| Jeung-Keun Kim | Chief Executive Officer | 0 | 1960 |
| Hirose Dakashi | Executive Officer | 0 | N/A |
| Jae-Sang Lee | Executive Officer | 0 | N/A |
| Ju-Won Kim | Executive Officer | 0 | N/A |
| Se-Nyun Kim | Executive Officer | 0 | N/A |
| Seung-Chul Lee | Executive Officer | 0 | 1963 |
| So-Jin Ahn | Executive Officer | 0 | N/A |
| Sung-Hee Son | Executive Officer | 0 | N/A |
| Sung-Ho Park | Executive Officer | 0 | 1968 |
| Su-Sung Lee | Executive Officer | 0 | N/A |
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.